Showing results (221-230 of 274) with videos related to
Sort By:
Pageof 28
Molecular Oncology|January 20, 2020
NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myelomaJiliang Xia, Yanjuan He, Bin Meng, et al.Blood Science (Baltimore, Md.)|May 25, 2023
Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphomaRu Li, Tingyu Wang, Rui Lyv, et al.Oncotarget|November 17, 2016
Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myelomaLihui Shi, Xiaoqi Qin, Huijun Wang, et al.Annals of Hematology|September 3, 2024
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS StudyWeijun Fu, Soo-Mee Bang, Honghui Huang, et al.Annals of Hematology|September 19, 2014
Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patientsGang An, Xiaoqi Qin, Chirag Acharya, et al.Annals of Hematology|May 23, 2025
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS studyWeijun Fu, Soo-Mee Bang, Honghui Huang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2026
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)Wenqiang Yan, Chenxing Du, Rui Lv, et al.Experimental Hematology|December 3, 2014
Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatmentGang An, Chirag Acharya, Shuhui Deng, et al.Clinical Lymphoma, Myeloma & Leukemia|November 19, 2022
Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUSWeijun Fu, Wei Li, Jianda Hu, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 29, 2016
Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemiaShuhua Yi, Zengjun Li, Dehui Zou, et al.Pageof 28